Melneurin (Melperone Hydrochloride)

Melperone hydrochloride works by blocking dopamine D2 receptors in the brain, which diminishes excessive dopaminergic activity that contributes to psychotic symptoms. It also moderately antagonises serotonin 5‑HT2 receptors, adding to its antipsychotic effect.

The exact dose of Melneurin is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Physicians typically start with a low dose and adjust gradually, following local prescribing guidelines.

Safety data for melperone hydrochloride in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Melneurin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Melneurin (melperone) belongs to the butyrophenone class, similar to haloperidol, but generally shows a lower incidence of extrapyramidal side effects. Its sedative profile may be more pronounced, and it offers an alternative when patients experience intolerance to other typical agents.

Melneurin should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperatures to maintain stability and potency.

Melneurin is administered orally. The tablet should be swallowed whole with a glass of water, preferably with or without food as directed by the prescriber. Do not crush or chew the tablet unless specifically instructed.

Serious risks include neuroleptic malignant syndrome, tardive dyskinesia, severe hypotension, seizures, agranulocytosis, and myocarditis. Patients should be monitored closely for signs such as high fever, muscle rigidity, sudden drop in blood pressure, or abnormal movements, and seek immediate medical attention if they occur.

Melneurin is contraindicated in individuals with known hypersensitivity to melperone or any excipients, those with severe central nervous system depression, and patients with a history of malignant hyperthermia. Caution is also advised for patients with significant cardiac, hepatic, or renal impairment.